Peace of mind for biomolecule analysis
Shimadzu has introduced the new “Nexera Bio” solution, a biocompatible Ultra-High Performance Liquid Chromatography (UHPLC) system. It offers the same superior reliability, robustness and expandability as other Nexera series UHPLC systems. It is particularly well suited for analyzing protein-based pharmaceuticals, antibody drugs and other substances developed or manufactured using biotechnologies. The Nexera Bio is compatible with mobile phase solvents containing high concentrations of salts or acids, and has also been designed to inhibit peak tailing caused by adsorption to tubing. The Nexera Bio is equipped with new and advanced product features such as maximum corrosion resistance, low surface activity and minimized sample loss.
The new “Nexera Bio” solution, the biocompatible Ultra-High Performance Liquid Chromatography (UHPLC) system of Shimadzu
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
